James Love's blog

Notes for the talk at Fordham on TPP/TTIP.

These were my notes from my talk on Thursday morning at the annual Fordham International IP conference, which is organized by Professor Hugh Hansen. The panel was titled "Examination of TPP & TTIP."


What is wrong with the TransPacific Partnership (TPP)?

The TPP was negotiated with asymmetric secrecy. Not from industry, but from the public. Nearly all of the real experts in IP policy were in the dark over the actual language of the texts. We delegated too much power to government trade negotiators and to lobbyists.

KEI statement on GSK's announcement of policies to expand access to patented medicines

GSK has made a major announcement of new policies to expand access to its patented medicines. A copy of the press statement is here.

The WSJ on Doha Declaration on TRIPS and Public Health, in 2001

This was the Wall Street Journal's take on the Doha Declaration on TRIPS and Public Health, two days after the agreement was reached:

Update on our work on US government owned patents

I have provided an update on our work on US government owned patents here:

KEI's March 4, 2016 submission to USTR regarding the Special 301 list

This is a slightly expanded version of the testimony we provided at the March 1, 2016 USTR Special 301 hearing. I had some trouble uploading to Regulations.Gov, but emailed a copy to Christine R. Peterson, the Director for Intellectual Property and Innovation. One addition was this data:

2016: Did Army do analysis to determine if public is better off with exclusive license to patent?

We sent this brief note to the Army today regarding this federal register note: https://federalregister.gov/a/2016-04494



From: Jamie Love
Date: Sat, Mar 5, 2016
To: Phoebe.E.Lenear@usace.army.mil
Subject: Digital Optical Method patents

I am writing about the notice of intent for an exclusive license to patents on the Digital Optical Method (DOMTM ), United States Patent No. 7,495,767.

KEI comments to the Senate Finance Committee Report on the Price of Sovaldi

On March 4, 2016, KEI provided comments to the US Senate Committee on Finance on a report prepared by staff for Senators Grassley and Wyden that was issued by the committee on December 2015, titled “The Price of Sovaldi and Its Impact on the U.S. Health Care System.” Senators Grassley and Wyden asked the public to comment on various issues raised in the report. The comments we filed on March 4 included three major sections.

Colombia takes an important step in defining the public interest in compulsory licensing case

(More on Colombia here: http://keionline.org/colombia)

Andrea Carolina Reyes Rojas informs us that a committee appointed to consider a request for a compulsory license on the leukemia drug Imatinib has decided that there are public interest reasons to do so.

A copy of the decision is available here. Andrew Goldman shares some thoughts and context here.

KEI submissions to the UN Secretary General's High Level Panel on Access to Medicine

Attached below are the four submissions for which KEI was the lead author to the UN Secretary General's High Level Panel (HLP) on Access to Medicine.

  1. "The Need for Global Negotiations on Agreements to Fund R&D within the Context of a Progressive De-linking of R&D Costs from Product Prices". Supported by 12 organizations; 1 individual; 3 Members of European Parliament.
  2. "Increasing the Transparency of Markets for Drugs, Vaccines, Diagnostics and other Medical Technologies". Supported by 17 organizations; 2 individuals; 3 Members of European Parliament.

DHHS Declared public health emergency for Zika virus

DHHS has declared a public health emergency over the Zika viru, and authorized emergency use of diagnostic tests. (Copy here)

Notes from KEI's testimony at today's USTR Special 301 hearing

(An expanded, edited and better version of this is available in our March 4, 2016 reply comment to USTR, available here: http://www.keionline.org/node/2440)

These were my notes from my testimony for KEI at today's USTR Special 301 hearing

Big market puts countries on the #special301 watch list

Schedule for the March 1, 2016 USTR Special 301 Hearing

KEI is one of the non-government entities speaking at the USTR Special 301 hearing on Tuesday. We each get 7 minutes of testimony and 3 minutes of questions. (The schedule is here).

Equitable Access Initiative (EAI), 1st intervention

I am in a meeting of the Equitable Access Initiative (EAI), which is considering new ways of measuring development and/or health needs, in the context of the priority setting by donors. I am a member of the Expert Panel, and this was my intervention in the morning session:

The presentations by John McArthur and Dominik Zotti were excellent, and the work of the four expert groups is a very useful contribution for those struggling with the challenge of setting priorities for aid.

5 questions about NIH licenses to patents on Production of Attenuated Respiratory Syncytial Virus Vaccines

The NIH has a notice for comments on proposed licenses of several patents relating to the "Production of Attenuated Respiratory Syncytial Virus Vaccines". See: https://federalregister.gov/a/2016-03486

We asked Peter Soukas, a Senior Technology Licensing Specialist in the Technology Transfer and Intellectual Property Office, at the National Institute of Allergy and Infectious Diseases (NIAID), these questions:

  1. What provisions exist in the license to protect US residents against excessive or unreasonable pricing?
Syndicate content